Kura Oncology Inc (KURA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

2017-11-22
Price :
Published : Nov-2017
No. of Pages : 46
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11
Venture Financing 12
Kura Oncology Raises USD91.69 Million in Venture Financing 12
Merger 13
Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 13
Licensing Agreements 14
Kura Oncology Amends Licensing Agreement with Janssen Pharma 14
Kura Oncology Amends its Licensing Agreement with University of Michigan 16
Equity Offering 17
Kura Oncology Prices Public Offering of Shares for USD50 Million 17
Kura Oncology Raises USD50 Million in Public Offering of Shares 19
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 21
Kura Oncology Inc - Key Competitors 23
Kura Oncology Inc - Key Employees 24
Kura Oncology Inc - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 07, 2017: Kura Oncology Reports Second Quarter 2017 Financial Results 26
May 15, 2017: Kura Oncology Reports First Quarter 2017 Operational and Financial Results 27
Mar 14, 2017: Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results 29
Nov 07, 2016: Kura Oncology Reports Third Quarter 2016 Financial Results 30
Aug 10, 2016: Kura Oncology Reports Second Quarter 2016 Financial Results 31
May 11, 2016: Kura Oncology Reports First Quarter 2016 Financial Results 32
Mar 17, 2016: Kura Oncology Reports Fourth Quarter and Full Year 2015 Operational and Financial Results 33
Corporate Communications 35
Jan 03, 2017: Kura Oncology Appoints Steven Stein, M.D. to Board of Directors 35
Product News 36
01/04/2017: Kura Oncology Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program 36
Clinical Trials 37
Apr 07, 2017: Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947 37
Apr 05, 2017: Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 38
Apr 05, 2017: Kura Oncology Presents Preclinical Data on KO-539 at the American Association for Cancer Research Annual Meeting 2017 39
Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-539 at AACR Annual Meeting 2017 40
Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-947 at AACR Annual Meeting 2017 41
Jan 04, 2017: Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 42
Dec 01, 2016: Kura Oncology Presents Data on Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 43
Dec 01, 2016: Kura Oncology Presents Preclinical Data on KO-947 the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 44
Nov 15, 2016: Kura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Kura Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kura Oncology Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11
Kura Oncology Raises USD91.69 Million in Venture Financing 12
Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 13
Kura Oncology Amends Licensing Agreement with Janssen Pharma 14
Kura Oncology Amends its Licensing Agreement with University of Michigan 16
Kura Oncology Prices Public Offering of Shares for USD50 Million 17
Kura Oncology Raises USD50 Million in Public Offering of Shares 19
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 21
Kura Oncology Inc, Key Competitors 23
Kura Oncology Inc, Key Employees 24
Kura Oncology Inc, Other Locations 25

List of Figures
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Filed in: Pharmaceutical
Publisher : GlobalData